ES2106096T3 - Procedimiento para asegurar glutation intracelular adecuado en el tejido. - Google Patents

Procedimiento para asegurar glutation intracelular adecuado en el tejido.

Info

Publication number
ES2106096T3
ES2106096T3 ES92101515T ES92101515T ES2106096T3 ES 2106096 T3 ES2106096 T3 ES 2106096T3 ES 92101515 T ES92101515 T ES 92101515T ES 92101515 T ES92101515 T ES 92101515T ES 2106096 T3 ES2106096 T3 ES 2106096T3
Authority
ES
Spain
Prior art keywords
glutation
tissue
procedure
ensure suitable
suitable intracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92101515T
Other languages
English (en)
Inventor
David A Mark
W Bruce Rowe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Nestle SA
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA, Nestle SA filed Critical Societe des Produits Nestle SA
Application granted granted Critical
Publication of ES2106096T3 publication Critical patent/ES2106096T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE PROPORCIONA UN COMPUESTO PARA AUMENTAR Y/O MANTENER EL NIVEL DEL GLUTATIONE INTRACELULAR. DE ACUERDO CON LA INVENCION, LOS COMPUESTOS QUE INCLUYEN PROTEINAS HIDROLIZADAS ENRIQUECIDAS CON CISTEINA SE ADMINISTRAN COMPLETAMENTE AL PACIENTE. ADICIONALMENTE, PODRA ADMINISTRARSE EL GLUTATIONE CON LA PROTEINA HIDROLIZADA.
ES92101515T 1991-02-04 1992-01-30 Procedimiento para asegurar glutation intracelular adecuado en el tejido. Expired - Lifetime ES2106096T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65022291A 1991-02-04 1991-02-04

Publications (1)

Publication Number Publication Date
ES2106096T3 true ES2106096T3 (es) 1997-11-01

Family

ID=24608000

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92101515T Expired - Lifetime ES2106096T3 (es) 1991-02-04 1992-01-30 Procedimiento para asegurar glutation intracelular adecuado en el tejido.

Country Status (9)

Country Link
EP (1) EP0502313B1 (es)
JP (1) JPH04327537A (es)
AT (1) ATE155344T1 (es)
AU (1) AU652988B2 (es)
CA (1) CA2060560C (es)
DE (1) DE69220821T2 (es)
DK (1) DK0502313T3 (es)
ES (1) ES2106096T3 (es)
GR (1) GR3024638T3 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214062A (en) * 1992-04-08 1993-05-25 Clintec Nutrition Co. Method and composition for treating immune disorders, inflammation and chronic infections
AU5040493A (en) * 1992-11-30 1994-06-09 Transcend Therapeutics, Inc Method for treating systemic inflammatory response syndrome
AU6060694A (en) * 1993-05-10 1994-11-17 Transcend Therapeutics, Inc Method for treating acquired immune deficiency syndrome
US5578576A (en) * 1994-09-02 1996-11-26 Dalhousie University Method and composition for treating intestinal wounds or ulcers
US5821217A (en) * 1995-10-27 1998-10-13 Beth Israel Deaconess Medical Center, Inc. Enteral formulation: low in fat and containing protein hydrolysates
US6251857B1 (en) 1995-12-14 2001-06-26 Novelos Therapeutics, Inc. Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
RU2089179C1 (ru) * 1995-12-14 1997-09-10 Закрытое акционерное общество "ВАМ" Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
RU2144374C1 (ru) 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
US20070142267A1 (en) 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
BRPI0414505A (pt) * 2003-09-19 2006-11-07 Nutricia Nv uso de carboidratos solúveis em água digerìveis e de um ou mais promotores da glutationa, e, composição
JP2006219458A (ja) * 2005-02-14 2006-08-24 Meiji Milk Prod Co Ltd 虚血性腸疾患抑制剤
JP5784869B2 (ja) * 2008-04-28 2015-09-24 太陽化学株式会社 抗炎症剤
CN101880702B (zh) * 2009-05-07 2012-12-12 成都自豪药业有限公司 一种采用产朊假丝酵母发酵生产谷胱甘肽的方法
KR102601321B1 (ko) * 2015-07-30 2023-11-10 메르크 파텐트 게엠베하 세포 내 글루타티온 수준을 증가시키는 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2459620B1 (fr) * 1979-06-26 1983-08-05 Agronomique Inst Nat Rech Hydrolisat enzymatique total de proteines de lactoserum, obtention et application
FR2544613B1 (fr) * 1983-04-20 1985-10-25 Roussel Uclaf Nouvelles compositions destinees a etre utilisees en dietetique, en reanimation et en therapeutique, renfermant une fraction proteique a base de trois types de minipeptides
EP0357776A4 (en) * 1987-05-14 1991-01-30 Terumo Kabushiki Kaisha Egg white hydrolyzate
CA1338682C (en) * 1988-12-23 1996-10-29 Gustavo Bounous Biologically active undenatured whey protein concentrate as food supplement

Also Published As

Publication number Publication date
CA2060560C (en) 2002-07-23
ATE155344T1 (de) 1997-08-15
AU652988B2 (en) 1994-09-15
CA2060560A1 (en) 1992-08-04
DE69220821T2 (de) 1997-11-20
EP0502313B1 (en) 1997-07-16
AU1065992A (en) 1992-08-06
EP0502313A3 (en) 1993-05-12
EP0502313A2 (en) 1992-09-09
GR3024638T3 (en) 1997-12-31
JPH04327537A (ja) 1992-11-17
DE69220821D1 (de) 1997-08-21
DK0502313T3 (da) 1998-02-02

Similar Documents

Publication Publication Date Title
ES2106096T3 (es) Procedimiento para asegurar glutation intracelular adecuado en el tejido.
ATE75945T1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
ATE209864T1 (de) Zusammensetzung zur behandlung von patienten mit lebererkrankungen
DE3883035D1 (de) Saponinkomplexe mit phospholipiden und sie enthaltende pharmazeutische und kosmetische zusammensetzungen.
CO4970691A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
ATE196428T1 (de) Verwendung von gentisinsäure oder gentisylalkohol zur stabilisierung von radio-markierten peptiden und proteinen
DE3772521D1 (de) Insulinzubereitung fuer nicht-parenterale verabreichung.
ATE84968T1 (de) Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
SE8802569L (sv) Foerbaettringar vid eller avseende somatosstatiner
ATA204590A (de) Pharmazeutische zubereitung auf basis von lys-plasminogen
ES2092539T3 (es) Uso de derivados de la tiazolidina-4-carboxilato para el tratamiento de enfermedades pulmonares.
ATE213499T1 (de) Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
ATE107168T1 (de) Verwendung von gepiron zur herstellung eines pharmazeutischen präparats zur behandlung atypischer depression.
WO1991015200A3 (en) Use of trinitrobenzenes or carminic acid in the treatment of cancer or viral diseases
ES2054942T3 (es) Procedimiento para la determinacion de fructuosaminas.
DE69318166D1 (de) Mit morphogen angereicherte nahrungszusammenstellung
ES2032209T3 (es) Derivados de proteinas que contienen hierro en forma altamente biodisponible, su preparacion y composiciones farmaceuticas que los contienen.
ATE96035T1 (de) Verwendung eines polypeptides mit gammainterferon-aktivitaet zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von primitivem pleura-krebs.
IT1283134B1 (it) Derivati sintetici e semisintetici di somatostatine utili nella stimolazione della crescita corporea, in particolare in
DK608686D0 (da) 4-thienyl-dihydropyridiner, fremgangsmaade til deres fremstilling og deres anvendelse i laegemidler
ECSP982669A (es) Terapia en combinacion para erradicar vhc -arn detectable en pacientes que padecen infeccion de hetatitis c cronica

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 502313

Country of ref document: ES